Undisclosed CALR × CDK9 pADC / Prelude Therap - LARVOL DELTA

Discovery of first-in-class calr-targeted precision ADCs delivering a CDK9degrader payload for the treatment of calr-mutated MPNs (ASH 2025) - "Treatmentwas well tolerated, with no off-target effects observed in healthy hematopoietic cells.In summary, we describe a first-in-class CALR-targeted ADC that delivers a novel CDK9 degrader payload,selectively eliminating CALR-mutant MPN progenitors. These results support further development of amutant CALR x CDK9 degrader pADC as a potential disease-modifying therapeutic for CALR-mutantMPNs."

Essential Thrombocythemia • Hematological Malignancies • Myeloproliferative Neoplasm • Thrombocytosis • CALR • CD34 • HSP90AA1 • JAK2

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs (GlobeNewswire) - "First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms....The Company has completed GLP toxicology studies and anticipates filing the IND and initiating a phase 1 study in the first quarter of 2026....First disclosure of a mutant calreticulin (mCALR) targeted degrader antibody conjugate (DAC) with a novel CDK9 degrader payload."

CALR • IND • JAK2V617F • Preclinical • Myeloproliferative Neoplasm

Mutated calreticulin (mCALR) DAC discovery program (GlobeNewswire) - "Updated preclinical data from this program has been accepted for oral presentation at the American Society of Hematology (ASH) 67th Annual Meeting taking place in Orlando, FL December 6-9, 2025."

CALR • Preclinical • Essential Thrombocythemia • Myelofibrosis

Prelude Therapeutics…announced the publication of two abstracts with preclinical data on the Company’s JAK2V617F mutant selective inhibitors and CALR-targeted degrader antibody conjugates (DACs) discovery program, both accepted for oral presentation at the American Society of Hematology (ASH) 67th Annual Meeting… (GlobeNewswire) - "These compounds demonstrate mutant specific inhibition in multiple preclinical models of myeloproliferative neoplasms (MPNs)."

CALR • JAK2V617F • Preclinical • Myeloproliferative Neoplasm